Cognitive dysfunction is a recognized feature of mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD). Cognitive impairment is associated with poor overall functional outcome and is therefore an important feature of illness to optimize for patients' occupational and academic outcomes. While generally people with BD appear to have a greater degree of cognitive impairment than those with MDD, direct comparisons of both patient groups within a single study are lacking. There are a number of methods for the assessment of cognitive function, but few are currently used in clinical practice. Current symptoms, past course of illness, clinical features, such as the presence of psychosis and comorbid conditions, may all influence cognitive function in mood disorders. Despite the general lack of assessment of cognitive function in clinical practice, clinicians are increasingly targeting cognitive symptoms as part of comprehensive treatment strategies. Novel pharmacological agents may improve cognitive function, but most studies of standard mood stabilizers, such as lithium and the anticonvulsants, have focused on whether or not the medications impair cognition. Non-pharmacological strategies, such as cognitive remediation and exercise, are increasingly studied in patients with mood disorders. Despite the growing interest in strategies to manage cognitive function, there is a paucity of high-quality trials examining either pharmacological or non-pharmacological modes of intervention.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/pcn.12463 | DOI Listing |
iScience
January 2025
Cognitive Neuroimaging Unit, CEA, INSERM, Université Paris-Saclay, NeuroSpin Center, 91191 Gif/Yvette, France.
Recent studies showed that humans, regardless of age, education, and culture, can extract the linear trend of a noisy scatterplot. Although this capacity looks sophisticated, it may simply reflect the extraction of the principal trend of the graph, as if the cloud of dots was processed as an oriented object. To test this idea, we trained Guinea baboons to associate arbitrary shapes with the increasing or decreasing trends of noiseless and noisy scatterplots, while varying the number of points, the noise level, and the regression slope.
View Article and Find Full Text PDFFront Psychol
January 2025
Department for Clinical Psychology and Psychotherapy, Philipps University Marburg, Marburg, Germany.
Background: Several studies identified affect-regulatory qualities of deceptive placebos within negative and positive affect. However, which specific characteristics of an affect-regulatory framing impacts the placebo effect has not yet been subject to empirical investigations. In particular, it is unclear whether placebo- induced expectations of direct emotion inhibition or emotion regulation after emotion induction elicit stronger effects in affect regulation.
View Article and Find Full Text PDFRisk Manag Healthc Policy
January 2025
Department of Medical Rehabilitation Science, Faculty of Applied Medical Sciences, Umm Al-Qura University-Makkah-Saudi Arabia; Cairo University, Cairo, Egypt.
Introduction: Dual tasking (DT) requires individuals to carry out two actions simultaneously, comparable to how the brain can perform a cognitive function while the body is in motion, which eventually enhances human balance. This paper aims to examine and compare the impact of DT on the risk of falling (ROF) among Saudi female students.
Methods: A cross-sectional design was used.
EClinicalMedicine
February 2025
Department of Psychiatry, Chaohu Hospital of Anhui Medical University, Hefei, Anhui, China.
Background: Brain stimulation therapy (BST) has significant potential in treating psychiatric, movement, and cognitive disorders. Given the high prevalence of comorbidities among these disorders, we conducted an umbrella review to comprehensively assess the efficacy of BSTs in treating the core symptoms across these three categories of disorders.
Methods: We systematically searched for meta-analyses and network meta-analyses of randomized controlled trials with sham controls up to September 25, 2024, from databases including PubMed, PsycINFO, Embase, and the Cochrane Library.
Drug Des Devel Ther
January 2025
Department of Anesthesiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, Fujian, People's Republic of China.
Purpose: While esketamine shows promise as an adjunct in procedural sedation, its impact on postoperative cognitive recovery remains incompletely characterized. This study investigated the effects of esketamine on multiple dimensions of recovery, particularly cognition, in patients undergoing colonoscopy with propofol-based sedation.
Patients And Methods: We conducted this randomized, double-blinded, placebo-controlled trial from January 6, 2023, to May 20, 2024, at two hospitals in China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!